These results indicate that the synergistic response to dual inhibition of BCL2L1 activity and AKT phosphorylation is cancer cell line-specific and can be predicted by the presence of drug targets in the cell line functional oncogene signature. This evidence concerns the gene BCL2L1 and cancer.